Symic Bio to Present at the 28th Annual Piper Jaffray Healthcare Conference

Tuesday, November 22, 2016 General News
Email Print This Page Comment
Font : A-A+

SAN FRANCISCO, Nov. 22, 2016 /PRNewswire/ -- Symic Bio, a clinical stage biopharmaceutical company focused on extracellular

matrix biology developing a new category of therapeutics, today announced that Ken Horne, Chief Executive Officer, will present an overview of the company pipeline and progress at the upcoming Piper Jaffray Healthcare Conference.

Conference details are as follows:

               Date: Tuesday, November 29, 2016

               Time: 7:30 a.m. EST

               Location: Lotte New York Palace, New York

About Symic Bio

Symic Bio is a clinical stage biopharmaceutical company focused on extracellular matrix biology that is developing a new category of therapeutics. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules of the extracellular matrix. Symic Bio currently has two clinical candidates, SB-030 for the treatment of critical limb ischemia and SB-061 directed at disease modification in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.

For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.

Investor Contacts

Lisa Burns or Bill Slattery, Jr. Burns McClellan, Inc.(212) 213-0006 ir@symic.bio

Media Contacts

David Schull or Rich AllanRusso Partners, LLC(212) 845-4271(646) 942-5588david.schull@russopartnersllc.com rich.allan@russopartnersllc.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/symic-bio-to-present-at-the-28th-annual-piper-jaffray-healthcare-conference-300367247.html

SOURCE Symic Bio



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook